Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090, Wien, Austria. hans.lassmann@meduniwien.ac.at
Hans
H
Lassmann
D000818:Animals; D001253:Astrocytes / Q000187:drug effects*; D001812:Blood-Brain Barrier / Q000187:drug effects*; D002518:Ceramides / Q000378:metabolism*; D003711:Demyelinating Diseases / Q000517:prevention & control*; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D009103:Multiple Sclerosis / Q000503:physiopathology*; D016328:NF-kappa B / Q000378:metabolism*; D009836:Oligodendroglia / Q000187:drug effects*; D011409:Propylene Glycols / Q000494:pharmacology*; D015363:Quinolones / Q000494:pharmacology*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000494:pharmacology
D002518:Ceramides; D007166:Immunosuppressive Agents; D016328:NF-kappa B; D011409:Propylene Glycols; D015363:Quinolones; C476223:laquinimod; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine